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Background. Few European countries conduct reactive surveillance of influenza mortality, whereas most monitor morbidity.
Methodology/Principal Findings. We developed a simple model based on Poisson seasonal regression to predict excess
cases of pneumonia and influenza mortality during influenza epidemics, based on influenza morbidity data and the dominant
types/subtypes of circulating viruses. Epidemics were classified in three levels of mortality burden (‘‘high’’, ‘‘moderate’’ and
‘‘low’’). The model was fitted on 14 influenza seasons and was validated on six subsequent influenza seasons. Five out of the
six seasons in the validation set were correctly classified. The average absolute difference between observed and predicted
mortality was 2.8 per 100,000 (18% of the average excess mortality) and Spearman’s rank correlation coefficient was 0.89
(P=0.05). Conclusions/Significance. The method described here can be used to estimate the influenza mortality burden in
countries where specific pneumonia and influenza mortality surveillance data are not available.
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Data. PLoS ONE 2(5): e464. doi:10.1371/journal.pone.0000464
INTRODUCTION
Influenza epidemics occur each winter, causing substantial
morbidity and mortality worldwide [1]. The clinical severity of
influenza increases with age and in individuals with underlying
health disorders [2]. During seasonal epidemics more than 90% of
all influenza-related deaths involve persons aged 65 years and
more [3].
The mortality impact is highly variable from year to year [4].
The highest mortality rates typically occur in seasons when
influenza A (H3N2) viruses predominate, rather than influenza A
(H1N1) and B viruses [5].
Few European countries conduct reactive surveillance of
influenza mortality, but most monitor influenza morbidity and
virological characteristics [6]. Estimates of the influenza mortality
burden generally become available 2–3 years after the correspond-
ing epidemic and are usually based on post-hoc analysis of national
pneumonia and influenza (P&I) mortality statistics. For public
health purposes, knowledge on influenza mortality can have
important practical implications. Firstly, people and particularly
the representatives of health authorities ‘‘want to know’’. Secondly,
real-time predictions of mortality could theoretically help planning
hospitals needs or deciding on antiviral or vaccine interventions.
Here we describe a simple model designed to predict the weekly
excess of P&I mortality in persons aged 65 years or more, based on
influenza morbidity data and the types/subtypes of circulating
viruses.
METHODS
The weekly numbers of P&I deaths in France were obtained from
death certificates collected by the Centre d’e ´pide ´miologie sur les causes
me ´dicales de de ´ce `s between October 1984 and December 2004. We
identified P&I deaths in persons aged 65 years and older by using
codes 480–487 of the International Classification of Diseases
(ICD)-9
th revision up to 31 December 1999, and codes J10–J11,
J12–J18 of the ICD-10
th revision after 1 January 2000.
Morbidity data were obtained after 1984 from the Sentinelles
system, [www.sentiweb.org] [7], a French nationwide network of
general practitioners who report, in real time, the number of
consultations for influenza-like illness (ILI). ILI is defined as
sudden-onset fever above 39uC with respiratory symptoms and
stiffness or myalgias. The age, sex, vaccination status and location
of cases is also reported. By using population data from regular
censuses [http://www.insee.fr/fr/ffc/ipweb/ip1089/ip1089.xls],
we calculated weekly ILI incidence rates. The weekly proportion
of patients over 65 years was used as a proxy for the ILI age
distribution.
For each influenza season, we extracted from available data ([8]
and the European Influenza Surveillance Scheme [www.eiss.org])
the dominant types and subtypes of circulating influenza viruses in
France (one or two types per epidemic).
We first applied a Poisson seasonal regression model to
morbidity data in order to estimate the baseline seasonal ILI
incidence [9,10]: the model was estimated based on non-epidemic
data, defined as a weekly morbidity rate below 279 cases per
100,000 inhabitants. Seasonality was modeled by introducing
periodic functions of time as covariates. The model also included
a linear function of time for capturing the secular time trend in the
data that may be due to demographic changes (e.g. population
aging). Predicted baseline seasonal ILI incidence rates were used to
define epidemic periods, i.e. when the observed ILI rate exceeded
the 95 percent confidence limit of the predicted baseline ILI rate
for two consecutive weeks. The difference between observed and
predicted baseline ILI rates during epidemic periods was used to
define excess ILI morbidity.
We then applied a similar strategy to P&I mortality data: We
fitted a Poisson seasonal regression model to weekly mortality data
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epidemic periods. We extended the ILI epidemic periods by two
weeks in order to deal with the potential delay between symptom
onset and death attributable to influenza. A dummy variable was
introduced to take into account the change in the version of the
ICD classification [11], so that we could estimate in the model the
conversion factor resulting from this modification. Excess P&I
mortality was calculated as the difference between observed P&I
mortality and predicted baseline seasonal mortality, during
epidemic weeks. Epidemics were further classified in three levels
of mortality burden (‘‘high’’, ‘‘moderate’’ and ‘‘low’’) according to
the tertiles of the observed excess mortality distribution.
Finally, we fitted a Poisson regression model predicting weekly
excess P&I mortality in persons aged 65 years or more from the
weekly excess ILI morbidity, the weekly proportion of cases aged
65 years or more out of all ILI , and the dominant influenza virus
types or subtypes (A/H3N2, A/H1N1, B). The model was
estimated over 14 winter periods between October 1984 and
October 1998, and validated over 6 winter periods between
October 1998 and December 2004. The conversion factor
estimated from the mortality seasonal model was introduced to
correct estimations after year 2000. We tested morbidity and
mortality data simultaneously, lagged by one week, and lagged by
two weeks, and we selected the best model. Deviance statistics
were used for model selection, and parameters were tested using
the Wald chi-square method. Average absolute differences
between observed and predicted values and Spearman’s rank
correlations were used to assess predictability. All analyses were
done with SAS software, version 9.1 (SAS institute, Cary, NC).
RESULTS
The P&I mortality, ILI morbidity weekly data and the dominant
types/subtypes of circulating influenza viruses are given Figure 1.
The highest mortality rate was observed in winter 1989/1990,
when A/H3N2 viruses were circulating. The highest ILI
morbidity rate was observed during winter 1988/1989, when A/
H1N1 viruses were circulating.
Between 1984 and 2004 the model of baseline seasonal ILI
morbidity identified 20 epidemic periods, observed from the
second week of November to the first week of May, and lasting
from 6 to 15 weeks. Excess ILI morbidity ranged from 0 to 1387
cases per 100,000 inhabitants per week, with a median of 222 per
100,000 inhabitants per week.
Excess P&I mortality ranged from 0 to 9.4 per 100,000
inhabitants over 65 years of age and per week (during winter
1989/1990),withamedianof1.4deathsper100,000inhabitantsper
week. The conversion factor considering the change in ICD
classification was estimated to 0.57 (95% CI 0.56–0.58) in the
seasonal model. The case-fatality ratio of influenza, defined here as
the ratio of cumulated excess mortality to cumulated excess
morbidity in people over 65 years of age, ranged from 0.53% for
the 2002/2003epidemicto3.10%forthe 1990/1991 epidemic.The
Figure 1. Observed and baseline seasonal rates of P&I mortality
a and ILI morbidity
b. The dominant types and subtypes of circulating influenza
viruses in France, 1984–2004, are shown in the rectangles. The case-fatality ratio of influenza is defined as the ratio of cumulated excess mortality to
cumulated excess morbidity in people over 65 years of age. P&I: pneumonia and influenza. ILI: influenza-like illness.
a rates per week and per 100,000
inhabitants over 65 years of age.
b rates per week and per 100,000 inhabitants.
doi:10.1371/journal.pone.0000464.g001
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A/H1N1 and 1.38% for B viruses (P=0.12, Kruskall-Wallis test).
One hundred and forty-five weeks were used to estimate the
P&I mortality Poisson predictive model, and 70 weeks were used
for validation (Figure S1). The best selected model used excess ILI
morbidity (P,0.001), and the proportion of cases aged 65 years or
more out of all ILI (P,0.001) both lagged by one week. A
dominant type B influenza virus was associated with less excess
mortality (P=0.023). No association was found between the
proportion of cases aged 65 years or more out of all ILI and the
dominant types or subtypes of circulating influenza viruses
(P=0.13, Kruskall-Wallis test). Cumulated excess P&I mortality
was classified in three tertiles, using 9.4 and 23.9 deaths per
100,000 inhabitants over 65 years as cut-off values. The model
adequately fitted P&I mortality (Figure 2). The average absolute
differences between observed and predicted values were 4.8 deaths
per 100,000 inhabitants (minimum 0.2, maximum 13.8, 22% of
the average observed excess) in the estimation set, and 2.8
(minimum 0.4 maximum 4.6, 18 % of the average observed
excess) in the validation set. The rank correlation between
observed and predicted values was 0.86 (P=0.001) in the
estimation set and 0.89 (P=0.05) in the validation set. Five out
of six epidemics of the validation set (one high, two moderate, and
two low) were correctly predicted. A discrepancy between the
observed (28.1, ‘‘high’’) and the predicted (23.8, ‘‘moderate’’)
burden was obtained for the 1998/1999 epidemic, but the
absolute difference was small.
DISCUSSION
Our simple seasonal regression model based on morbidity and
virological surveillance data provides accurate estimates of
pneumonia- and influenza-related mortality. Although a previous
study linked influenza morbidity to influenza mortality [12], ours
is the first to link excess influenza morbidity, i.e. morbidity above
the baseline observed during influenza epidemic periods, with
excess P&I mortality. Pneumonia is a frequent complication of
influenza and most influenza deaths result from secondary
bacterial pneumonia. Excess P&I mortality is a widely used and
sensitive indicator of influenza-associated death. [9]. This is why
we grouped pneumonia and influenza deaths together, instead of
treating them separately.
Our model does not use quantitative virological surveillance
data, which are available in several European countries. On the
other hand, laboratory testing for influenza infection is rare in case
of respiratory death, and many other respiratory viruses (e.g.
respiratory syncitial virus, human metapneumoviruses) may
contribute to P&I deaths [13]. In order to preserve consistency
between ILI and P&I, and also for reasons of simplicity, timeliness
and ease of access, qualitative information on the dominant
influenza virus type was used instead of quantitative virological
data. Diagnostic uncertainty in ILI as well as in P&I mortality may
increase the discrepancies between observed and predicted P&I
mortality.
Influenza is known to increase all-cause mortality [14–16]. We
did not try to predict all-cause influenza-associated mortality, but
a similar methodological approach could be used for this purpose.
Finally, we did not introduce influenza vaccine coverage (or
effectiveness) in people over 65 years of age. Although influenza
vaccine may prevent ILI or P&I deaths we postulated that
vaccination would not prevent influenza deaths without prevent-
ing influenza. Thus predictions of P&I deaths from ILI would not
be affected by introducing influenza vaccination in the model.
Figure 2. Observed and predicted excess P&I mortality cumulated by epidemic periods in persons over 65 years. Predicted values are presented
with their 95% confidence intervals. The red lines represent the tertiles of the observed P&I mortality. P&I: pneumonia and influenza. ICD:
International Classification of Diseases.
doi:10.1371/journal.pone.0000464.g002
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the focus of reactive surveillance, our method could be used to
predict excess P&I mortality almost in real time. It could guide
prevention strategies, when the P&I mortality is coming to an alert
level.
SUPPORTING INFORMATION
Figure S1 Weekly observed and predicted excess P&I mortality
in persons over 65 years. P&I: pneumonia and influenza
Found at: doi:10.1371/journal.pone.0000464.s001 (0.06 MB TIF)
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